Peptide blends: what is actually in the vial
A large part of what is sold is not a single compound but a mixture — two or three peptides in one vial, named after the combination. Search the name of one and every result is a shop. These pages say what is in it, what each component's evidence actually is, and what putting them in one vial costs you in being able to tell what is happening.
The same sentence is true of every blend on this page. No human trial has tested the combination. Each component carries whatever evidence it has separately, and mixing them does not add those together — for a mixture, the number that matters is the weakest component, not the strongest.
The most widely sold peptide blend there is: a growth-hormone-releasing hormone analogue paired with a selective ghrelin-receptor agonist, on the reas…
Two short peptides developed in Russia and approved there — one derived from a fragment of adrenocorticotropic hormone, the other from a fragment of t…
A copper-carrying tripeptide paired with the three-residue tail of alpha-melanocyte-stimulating hormone, sold for skin, wound healing and inflammatory…
Three unrelated substances sold as a metabolic or mitochondrial stack: a coenzyme present in every cell, a mitochondrial-derived peptide, and a small-…
Why a blend is harder to reason about than its parts
- You cannot change one thing at a time. A fixed mixture makes it impossible to attribute either a benefit or a problem to a component, or to stop one and keep the other.
- The supply problem multiplies. Every compound in the vial is another chance that identity, purity, sterility or endotoxin content is not what the label says — and a reaction cannot be traced to which one.
- Interactions between the components are unstudied. For every blend here, the pairing has no trial; where two components act on the same pathway, the usual argument that different mechanisms combine safely does not apply.
- The evidence of the strongest component gets borrowed by the rest. A mixture containing one well-studied compound is routinely described using that compound's evidence, as though it covered everything in the vial.
Every component links to its own monograph, where the evidence rating, the risks and the regulatory position are stated in full. The general risks that cross every compound in the library are on the safety page.